HC Wainwright & Co. Maintains Buy on BioXcel Therapeutics, Lowers Price Target to $85
HC Wainwright & Co. analyst Raghuram Selvaraju maintains BioXcel Therapeutics (NASDAQ:BTAI) with a Buy and lowers the price target from $110 to $85.
Earnings Scheduled For August 9, 2022
Companies Reporting Before The Bell
• Cognition Therapeutics (NASDAQ:CGTX) is estimated to report earnings for its second quarter.
Twitter Shares Surge Around 8%, Here’s 66 Biggest Movers From Yesterday
Gainers
Qurate Retail, Inc. (NASDAQ: QRTEB) shares climbed 71.1% to close at $5.20. Qurate Retail will host a conference call to discuss Q2 results on Friday, August 5th.
Mizuho Initiates Coverage On BioXcel Therapeutics with Buy Rating, Announces Price Target of $19
Mizuho analyst Graig Suvannavejh initiates coverage on BioXcel Therapeutics (NASDAQ:BTAI) with a Buy rating and announces Price Target of $19.
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 807 companies reached new 52-week lows.
BioXcel Therapeutics Q1 EPS $(1.12) Beats $(1.15) Estimate
BioXcel Therapeutics (NASDAQ:BTAI) reported quarterly losses of $(1.12) per share which beat the analyst consensus estimate of $(1.15) by 2.61 percent. This is a 3.7 percent decrease over losses of $(1.08) per share from
Earnings Scheduled For May 9, 2022
Companies Reporting Before The Bell
• Atlantica Sustainable (NASDAQ:AY) is likely to report quarterly loss at $0.08 per share on revenue of $277.90 million.
Attention Biotech Investors: Mark Your Calendar For May PDUFA Dates
The month of April was a mixed one for regulatory approvals. The Food and Drug Administration delayed approvals for at least three treatment candidates. New molecular entity, or NME, approvals, a measure of innovation in drug research, tapered to merely one for the month.